Riad Salem, MD MBA is Professor of Radiology, Surgery and Medicine, and System Vice-Chair, Image-Guided Therapy in the Department of Radiology at Northwestern University in Chicago, Illinois. He served as Section Chief of Interventional Radiology from June 2010-May 2025. He currently also System Vice-President, Operations, Interventional Services, for the Northwestern Memorial Healthcare system. He is a graduate of McGill University in Montreal, where he was recipient of the Wood Gold Medal, as well as the J Francis Award in Internal Medicine. He then completed his residency in Washington DC, a fellowship in interventional radiology (University of Pennsylvania), as well as a master’s in business administration (Finance). He is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has delivered >800 lectures nationally and internationally and written extensively on interventional oncology and TIPS, with >450 publications, >44000 citations, and an h index of 113. His current research focuses on advances in minimally invasive therapies for HCC and CRC, complex trans-splenic/mesenteric TIPS in patients with porto-systemic thrombosis, as well as prostate artery embolization. He serves as global PI of two, international, randomized phase III trials involving sorafenib +/- Y90 in HCC (STOP-HCC) and chemotherapy +/- Y90 in CRC (EPOCH); EPOCH was the first large-scale RCT to meet its endpoints in the field of interventional oncology. He was also lead investigator in LEGACY, the pivotal trial that led to the FDA’s first PMA device approval. In 2017, he was recipient of the SIR Leaders in Innovation Award and the 2022 annual Dotter lecturer. In 2023, he was awarded with the distinguished fellow award and in 2025, is the Rolf Gunther Award for Excellence and Innovation in Interventional Radiology, both from the Cardiovascular and Interventional Radiology Society of Europe. Currently, he is the global-PI for Emerald-Y90, a multicenter phase 2 study investigating the combination of Y90 with durvalumab/bevacizumab, as well as global co-PI of FRONTIER, a first-in-man phase 1 study exploring Y90 in recurrent glioblastoma multiforme.